These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 6730593)

  • 1. [Diagnosis and therapy of iron overload with desferrioxamine].
    Andres J; Stobbe H
    Z Gesamte Inn Med; 1984 Apr; 39(8):167-9. PubMed ID: 6730593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
    Perrimond H; Chagnon C; Moulanier I; Michel G; Guidicelli H; Bernard PJ
    Ann Pediatr (Paris); 1991 Mar; 38(3):175-84. PubMed ID: 2039185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
    el-Gholmy A; Khalifa AS; Rahman YA; el-Bagoury I
    J Trop Med Hyg; 1969 Jan; 72(1):22-6. PubMed ID: 5773810
    [No Abstract]   [Full Text] [Related]  

  • 5. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Idiopathic hemochromatosis--diagnosis and therapy].
    Schmidt U; Preu E; Tuschy U; Senf L; Herre K
    Z Gesamte Inn Med; 1984 Apr; 39(8):152-60. PubMed ID: 6730591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
    North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
    Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
    Kirimlidis S; Philippidis P; Drossos C; Economidis J
    Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
    [No Abstract]   [Full Text] [Related]  

  • 9. Desferrioxamine induced urinary iron excretion in thalassemia.
    Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
    Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hemosiderosis in a patient on regular hemodialysis: treatment by desferrioxamine.
    Baker LR; Barnett MD; Brozovic B; Cattell WR; Ackrill P; McAlister J; Nimmon C
    Clin Nephrol; 1976 Jul; 6(1):326-8. PubMed ID: 954239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transfusion haemosiderosis and chelation therapy.
    Ley TJ; Griffith P; Nienhuis AW
    Clin Haematol; 1982 Jun; 11(2):437-64. PubMed ID: 7042160
    [No Abstract]   [Full Text] [Related]  

  • 13. [Current possibilities in the therapy of iron overload].
    Cermák J
    Vnitr Lek; 1994 Sep; 40(9):605-8. PubMed ID: 7975366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Chelating therapy in beta-thalassemia].
    Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
    Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant primary hemochromatosis and beta-thalassemia trait: iron depletion by erythrocytapheresis and desferrioxamine.
    Cesana M; Mandelli C; Tiribelli C; Bianchi PA; Conte D
    Am J Gastroenterol; 1989 Feb; 84(2):150-2. PubMed ID: 2916524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy.
    Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI
    Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901
    [No Abstract]   [Full Text] [Related]  

  • 17. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
    Krüger N; Kijewski H; König R; Tillmann W; Schröter W
    Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemochromatosis or hemosiderosis? Initial misinterpretation of clinical symptoms and laboratory findings in a 62-year-old patient].
    Allgayer H; Romen W
    Z Gastroenterol; 2002 Apr; 40(4):249-54. PubMed ID: 11961734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapy and monitoring of hypersiderosis in chronic renal insufficiency.
    Hilfenhaus M; Koch KM; Bechstein PB; Schmidt H; Fassbinder W; Baldamus CA
    Contrib Nephrol; 1984; 38():167-74. PubMed ID: 6713893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemosiderosis and idiopathic hemochromatosis].
    Nowotny P
    Z Gesamte Inn Med; 1967 Dec; 22(24):799-806. PubMed ID: 5585476
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.